Aravive — Investor Presentation (May 2022)
54 slides from Aravive's investor presentation, May 11, 2022
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation May 2022 NASDAQ: ARAV
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally include statements tha
Slide 3: Developing Transformative Targeted Cancer Therapeutics
Developing Transformative Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Targeted Inhibition of GAS6/AXL Signaling Pathway @ Registrational Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) Ongoing Phase 1b trial demonstrated more than doubling of progression-
Slide 4: Experienced Management and Board of Directors
Experienced Management and Board of Directors CEO coo CFO. Gail Mcintyre, Ph.0., DABT ‘Scott Dove, Ph.D. Vinay Shah BOARD OF DIRECTORS AB Sak Exee Chairman ofthe Board Dtector Director Director Director Director Director Director FredEstwinen, "Amato Giectia,PhO. Peter, MD, John choker, —<SigudKik_—
Slide 5: Aravive Pipeline
Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Batiraxcept (AVB-500) OVARIAN CANCER Platinum Resistant (batraxcept + pacitaxel) CLEAR CELL RENAL CANCER + 4 Line (batiraxcept + cabozantin’ + nivolumab) + 20° Line (batiraxcept + cabezantnid) + I
Slide 6: Urgent Unmet Needs & Large Market Opportunities
Urgent Unmet Needs & Large Market Opportunities ~106K Addressable Patients & Potential to Expand into Other Cancers and Earlier Lines of Therapy @ PROC 5th leading cause of cancer deaths among women in U.S. ~I0% of patients diagnosed with advanced-stage disease ADDRESSABLE PATIENTS Us. _~12,000 EU ~
Slide 7: Upcoming Key Milestones
Upcoming Key Milestones Safety and Preliminary Activity from P2 ccRCC 3 PROC Top Line Trial Results — — Potential Approval of Additional Pb ccRCC Additional P1b and P2 Submit BLAfor PROC, if PROC BLA Trial Data ceRCC Trial Data trial successful — Initiate CTGF Clinical Additional P1b PDAC Additional
Slide 8: GAS6/AXL Signaling Pathway
GAS6/AXL Signaling Pathway Drives Activation, Migration and Invasion of Abnormal Cells Inhibiting GAS6 Preclinically + Anti-tumor activity in many tumor models, including ovarian, kidney, pancreatic, and breast + Blocks tumor invasion & metastasis + Overcomes acquired drug resistance + Ameliorates d
Slide 9: Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth
Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth Batiraxcept binds GAS6, preventing it GAS is the sole activating ligand of AXL fiom| kindling and activating AXE ©2022 fain, fe (3) 9
Slide 10: Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor
Batiraxcept (AVB-500): High Affinity, Highly Specific GAS6/AXL Inhibitor Modified AXL-Fc fusion protein Proprietary biomarker tests to monitor engineered for strong stability and very GAS6 levels High afnity fer CASE + Serum GAS6 levels associated with + ~200 fold greater affinity for human GAS6 eff
Slide 11: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
@ Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
Slide 12: Platinum-Resistant Ovarian Cancer Current Treatment Landscape
Platinum-Resistant Ovarian Cancer Current Treatment Landscape Need for Better Therapies: Progression-Free Survival is ~3 mos & Overall Survival ~12 mos Per current NCCN Clinical Practice Guidelines Clinical activity of paclitaxel in PROC! in Oncology, Version 3, for Ovarian Cancer + 13-22% ORR (NCCN
Slide 13: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and repeat dose study in healthy volunteers + 43 subjects participated; 42 dosed + Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs + No anti-drug antibodies (ADA) + 10 mg/kg (IV) a
Slide 14: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure
Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure Modeling Identified RP2D of 15 mg/kg * Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile + Exposure-response relationship identified by unsupervised computer
Slide 15: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3'7 Line of Therapy have Progressive Disease by their First CT Scan’ Largest change in Target Lesion Burden for Per-
Slide 16: Promising Responses in Patients in Later Lines of Therapy
Promising Responses in Patients in Later Lines of Therapy and < 3 Month Platinum-Free Interval Compared to Literature Invasive Tumors Resistant to Multiple Lines of Therapy Expected to Be Dependent on the GAS6/AXL Pathway CLINICALRESPONSE CLINICAL RESPONSE OF BATIRAXCEPT+ ssn OF CHEMOTHERAPY IN ae)
Slide 17: Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups
Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups * Clinical activity higher in patients who had not received bevacizumab prior to entering study — Phenomenon observed in other studies’ ~ Preclinical study showed bevacizumab treatment results in lower distribution of subsequent ant
Slide 18: P1b PROC: Biomarker May Enrich Response to Batiraxcept + Chemotherapy
P1b PROC: Biomarker May Enrich Response to Batiraxcept + Chemotherapy Response rate increases to 47% in the biomarker high subgroup administered batiraxcept + paclitaxel vs 35% in entire paclitaxel cohort PAC (N=22) | PLD (N=30) CRIPR for patients with | 7/ 15 (47%) 4/20* (20%) high sAXL/GAS6 (2 CRs
Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC
Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this, time + Endpoint Assessment: PFS per RECIST V1.1; radiological imaging
Slide 20: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 21: ccRCC Current Treatment Landscape
ccRCC Current Treatment Landscape Initially Positioning Batiraxcept in 2L+ with Ability to Expand to 1L + Limited treatment options for patients who have failed 1L * Cabozantinib is the predominant drug used in 2L+ ccRCC' * Clinical Activity: Confirmed objective response rate for (60mg) cabozantinib
Slide 22: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140) P'b Population: + 26 patients + Histologically confirmed metastatic ceRCC and progressed on/after a front-line treatment regimen + Patients previously treated with cabozantinib are excluded Phase2 Phase 1b a At least 1 prior l
Slide 23: Ph1b ccRCC: Representative of 2L+ ccRCC Population
Ph1b ccRCC: Representative of 2L+ ccRCC Population with 100% Having Received Prior Immunotherapy ety All P1b Patients ura eral eit) (N= 16) (N=10) ‘Age years, Mean (min, max) 61 (40, 81) 60 (40, 76) 62 (42, 81) Gender, M 22 (85%) 13 (81%) 9 (20%) Prior Number of Lines = 1 16 (62%) 9 (66%) 7 (70%) =e
Slide 24: P1b ccRCC Study: Safety Profile Consistent with Cabozantinib
P1b ccRCC Study: Safety Profile Consistent with the Established Safety Profile for Cabozantinib 45 mg/kg P1b 20 mg/kg P1b Safety a Van Ee Patients ( 16) Batiraxcept-Related Deaths 0 ) 0 Grade 3 Adverse Events (AEs), 4 (15.4%) 2.(12.5%) 2 (20%) related to Batiraxcept Events: HTN, Thrombocytopenia, _E
Slide 25: Depth and Duration of Response in P1b ccRCC
Depth and Duration of Response in P1b ccRCC: Batiraxcept + Cabozantinib Cchange from Baseline, () sesssssssoszssssss Weeks on Study {201-008 gy 101-006 102-001 102002 gy 103-001 gy 104-001 105-002 105-003 gy 105-008 106.001 107-002 107-008 107-005 107-006 } 107-007 109-001 j 101.003 101-005, 1 101-0
Slide 26: P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib
P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib + 42% confirmed response in cabozantinib + batiraxcept group; 17-28% confirmed response for cabozantinib alone’ + 71% progression-free survival at 7 month; ~50-60% for cabozantinib alone’ All P1b Patients | P1b 15 mg/kg P4b 20 mg/kg Efficacy
Slide 27: P1b ccRCC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker
P1b ccRCC: Pretreatment Serum sAXL/GASG is a Potential Biomarker Best Response AllP1b Patients P1b15mg/kg — P1b 20 mg/kg (n=25) 1 (n=16) (n=9) 1 PR for Patients with low sAXLIGAS6 0/5 (0%) 0/4 (0%) 0/1 (0%) Confirmed PR for Patients with high 11/20 (65%) 8/12 (67%) 2 3/8 (38%) SAXL/GAS6 ee Box Uncon
Slide 28: Batiraxcept Phase 3 Registrational Trial Design in ccRCC
Batiraxcept Phase 3 Registrational Trial Design in ccRCC FDA Recommendation: integrated P2/P3 study with interim analyses to look at futility in the biomarker low population and ORR for potential accelerated approval with PFS endpoint for full approval. Full protocol and statistical plan in preparat
Slide 29: Batiraxcept: Pancreatic Adenocarcinoma
Batiraxcept: Pancreatic Adenocarcinoma
Slide 30: Pancreatic Adenocarcinoma Current Treatment Landscape
Pancreatic Adenocarcinoma Current Treatment Landscape Unmet Need with Current Treatments Providing Modest Clinical Activity Gemcitabine + nab-paclitaxel used in 1L treatment for advanced pancreatic adenocarcinoma Clinical Activity’: + ORR 23% with 1 patient with CR (<1%) — 20% progressed at first sc
Slide 31: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design
Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma (NCT04983407) P4b Population: + Patients (N~20) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane®) as first-line treatment Phase 1b Phas
Slide 32: Ph1b PDAC Demographics
Phib PDAC Demographics All P1b Patients Safety 15 mg/kg Batiraxcept + Gemcitabine+ nab-Paclitaxel (N= 21) Age years, mean (min, max) 67 (49, 82) Gender, M 10 (48%) ECOG 0 10 (48%) fl 11 (52%) Metastatic disease 19 (91%) Data cutoffMay 3, 2022 2
Slide 33: Safety Profile Consistent with Gemcitabine + nab-Paclitaxel in P1b PDAC
Safety Profile Consistent with the Established Safety Profile for Gemcitabine + nab Paclitaxel or Underlying Disease In P1b PDAC Study All P1b Patients 15 mg/kg Batiraxcept + Gemcitabine+ nab- Paclitaxel (N= 21) Batiraxcept-Related Deaths 0 6 (29%) Events: Dizziness, Fatigue, Muscular weakness, Neut
Slide 34: Initial Anti-Tumor Activity from Phase 1b PDAC Trial
Initial Anti-Tumor Activity from Phase 1b PDAC Trial + Five patients (202-004, 202-005, 206-002, 213- 002and 214-001) experiencedresolution of one or more target ascist lesions; 208-002 and — 213-002have since progressed + Two of these patients (213-002and 214- 001)had CA19-9 level that decreasedto
Slide 35: Initial Anti-Tumor Activity from Phase 1b PDAC Trial
Initial Anti-Tumor Activity from Phase 1b PDAC Trial Best Response All P1b Patients 15 mg/kg Batiraxcept + Gemcitabine+ nab-Paclitaxel (N= 21) Confirmed Partial Response 4 (19%) Unconfirmed Partial Response 2 (10%) } ae Stable Disease T (33%) Progressive Disease 5 (24%) Not Evaluable 1 (5%) Not Appl
Slide 36: P1b PDAC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker
P1b PDAC: Pretreatment Serum sAXL/GAS6 is a Potential Biomarker ORR with Gemcitabine + nab-Paclitaxel is 23 %* All P1b Patients 15 mg/kg Batiraxcept + Gemcitabine+ nab- Paclitaxel (N= 21) PR for Patients with low SAXL/GAS6 0/6 (0%) Confirmed PR for Patients with high sAXL/GAS6 4/15 (27%) Unconfirmed
Slide 37: Financial Summary
Financial Summary $59.4 Million* —_ 21.0 Million* No Debt Cash Runway Cash and Cash Shares Expected to Fund Equivalents Outstanding Base Operating Plan into Q1 2023 # + Data ast 12012021 ‘Includes combined $20Mimestmentrom Eshelman Ventures, LLC and aheathcareocused nstistonalinvestorin 12022 (©2022
Slide 38: Appendix
Slide 39: Strong Biological Rationale for Batiraxcept in PROC
Strong Biological Rationale for Batiraxcept in PROC * AXL expressed in 0% (0 of 10) of normal ovarian tissue’ + AXL expressed in 73% (219 of 297) of all ovarian tumor samples, demonstrating that AXL expression is significantly higher (P < 0.0001) in ovarian carcinomas than normal ovarian epithelium?
Slide 40: Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma
Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma + Preclinical data demonstrated increased » Studies have reported AXL expression survival in combination with gemcitabine, correlates with worse outcome in clinical decreased fibrosis, and decreased tumor samples from pancreati
Slide 41: Strong Biological Rationale for Batiraxcept in ccRCC
Strong Biological Rationale for Batiraxcept in ccRCC GASB/AXL in ccRCC* * AXL plays significant role in ccRCC invasion & metastasis * AXL highly expressed in aggressive ccRCC tumors and associated with poor outcome * GASG/AXL signaling pathway is established therapeutic target to preventitreat metas
Slide 42: Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC
Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC Direct regulation of GAS6/AXL signaling by HIF Promotes Renal Metastasis through SRC and MET + Stress conditions in cell activate GAS/AXL signaling to allow cell to survive + Hypoxia (stress factor), typical in solid tumors, induces h
Slide 43: Strong Patent Protection
Strong Patent Protection Stanford Licensed IP 4 Patent Family — Expiration 2031 Us: 3 Issued Patents Worldwide: 10 Issued (2 HK Recorded) Patents (EP Validated In 18 EP Countries) 3 Pending Patent Applications Stanford-Batiraxcept Co-owned IP 3 Patent Families — Expirations 2032 / 2033 / 2035 Us: 3
Slide 44: Clinical Activity of Cabozantinib in 2L+ ccRCC
Clinical Activity of Cabozantinib in 2L+ ccRCC Clinical Activity Objective Response % (95% Cl) ‘Complete Response (%) Stable Disease (%) Progressive Disease (%) mPFS (months) (95% Cl) Safety Deaths (#) Grade >=3 Treatment Related AEsin More Than 10% of Patients (%) ‘Treatment Discontinuations Due to
Slide 45: Summary of 1L ccRCC Regimens
SUMMARY of 1L Nivolumab + Pembro + Axitinib! Nivo*Cabozantinib! | Lenvatinib+Pembro' | Cabozantinib PREFERRED NCCN: Ipitimumab* (N=432 pla) (N=323 nie) (N=355 Up) (N=79) REGIMENS (N=580 ITT nl, Keynote-426 ‘Checkmate ER CLEAR CABOSUN Version 3.2022 intipoor N=425) Category 1 Category 1 Category 1 Ca
Slide 46: Summary of 2L+ ccRCC Regimens
SUMMARY of 2 PREFERRED NCCN REGIMENS) Version 3.2022 ‘Cabozantinibt (N=330) METEOR Category 1 Lenvatinib + Everolimust (N=51) Study 205 Nivolumab (N=406) Checkmate 025 Category 1 Belzutifant PREFERRED NCCN REGIMEN Version 3.2022 Category 1 Median folow.up 19 months 17.8 months inimum of 14 months OR
Slide 47: Linear Regression on 1L ccRCC PFS vs ORR Demonstrates High Correlation
Linear Regression on 1L ccRCC PFS vs ORR Demonstrates High Correlation Linear Regression Calculator For your tate regeaton eaustion fo Yi era 9-oamaexs 142502 ‘ctasavon Summary ‘you con coat cp rm i caer tity verone Met ube steplnitry. but you som of 82206 ‘head ote at ey appuret crepancies ncaKisao
Slide 48: Linear Regression on 2L and 1L+2L ccRCC PFS vs ORR
Linear Regression on 2L and 1L+2L ccRCC PFS vs ORR Demonstrates High Correlation 8
Slide 49: Rates and Depth of Response Associated with Overall Survival in ccRCC
Rates and Depth of Response Associated with Overall Survival in ccRCC + Retrospective studies have shown that early tumor shrinkage (eTS) based on target lesion reduction from baseline to first post-baseline scan, has predictive value for targeted therapies in RCC (Grunwald 2015; Grunwald 2016) ropo
Slide 50: Strategic Collaborations
Strategic Collaborations 3DMeci Exclusive license agreement for development & commercialization of batiraxcept across all oncology indications in Greater China + $12M upfront payment received + $207M total potential development and commercial milestone payments; SOM development milestones achieved t
Slide 51: Potential Mechanism of Synergy Between AVB-500 and PARP Inhibitors
Potential Mechanism of Synergy Between AVB-500 and PARP Inhibitors + The association between AXL and DNA repair protein expression was reported by Balaji et al, for TNBC, NSCLC. and HNSCC patient cohorts, where higher AXL levels in patient tumors was associated with increased expression of multiple
Slide 52: Response Over Time in ccRCC: Batiraxcept + Cabozantinib
Response Over Time in ccRCC: Batiraxcept + Cabozantinib Pb AVB(IS me/kg)+Cabo Pb AVB(20 me/ke)+Cabo 1 © OOF OE ———— — ——— 102-001 e- ° ry CS Cl ST SN VO To CS ————————————— . 00 I — —— | SS Ol 104001 * To: oe’ 107.05 Ae: a 0, SE , 107.00" 00, —— 1. CO), Cf —_—————— Sn 109-002" mamta ° 15-006" A sk S
Slide 53: Response Over Time in Phase 1b PDAC Trial
Response Overtime in Phase 1b PDAC Trial Data cutoffMay 3, 2022 Patient iO FC TS 210? TT © 23 23 TT © 202-001" Se! 202.003 ©: 216-001 202-002 Ee a 202.008 23000 210-001 22.00 206-007" 213-007" or a 205-001 206-001" BSS 206-001 EEO Ongoing treatment 223.00" Discontinued from treatment Partial Respons
Slide 54: Developing Transformative Targeted Cancer Therapeutics
¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation May 2022 NASDAQ: ARAV (©2022 Aram, Ine